Aquatic Capital Management LLC Sells 14,223 Shares of Eli Lilly and Company (NYSE:LLY)

Aquatic Capital Management LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 37,217 shares of the company's stock after selling 14,223 shares during the period. Eli Lilly and Company makes up 0.8% of Aquatic Capital Management LLC's investment portfolio, making the stock its 16th biggest position. Aquatic Capital Management LLC's holdings in Eli Lilly and Company were worth $28,732,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in LLY. Highline Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. raised its holdings in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter worth approximately $58,000. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley reduced their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,017.00.

Eli Lilly and Company Trading Up 2.9 %

Shares of NYSE LLY traded up $25.21 during midday trading on Friday, hitting $884.94. The stock had a trading volume of 3,395,903 shares, compared to its average volume of 3,444,748. The company has a fifty day moving average price of $827.69 and a 200 day moving average price of $817.26. The company has a market capitalization of $839.07 billion, a price-to-earnings ratio of 75.57, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.